Tumour necrosis factor-α single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies

Rheumatology

Volumn 46, Issue 9, 2007, Pages 1411-1416

  Chinoy, H ^a   Salway, F ^a   John, S ^a   Fertig, N ^b   Tait, B D ^c   Oddis, C V ^b   Ollier, W E R ^a   Cooper, R G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Australian Red Cross   (Australia)

Author keywords

Antibodies; Dermatomyositis; HLA, TNF ; Myositis; Polymorphisms; Polymyositis

Indexed keywords

ADENINE; AMINO ACID TRANSFER RNA LIGASE; GUANINE; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA DQB1 ANTIGEN; THYMINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PATHOGENESIS; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MYOSITIS; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMYOSITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548242316     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem145     Document Type: Article

References (37)

1. Luppi P, Rossiello MR, Faas S, Trucco M. Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med 1995;73;381-93.
2. Cooper GS, Miller FW, Pancley JP. The role of genetic factors in autoimmune disease: Implications for environmental research. Environ Health Perspect 1999;107(Suppl 5):693-700.
3. Shamim EA, Rider LG, Miller FW. Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2000;12:482-91.
4. Chinoy H, Ollier WE, Cooper RG. Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies? Curr Opin Rheumatol 2004;16:707-13.
5. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996;39:1507-18.
6. Furuya T, Hakoda M, Higami K et al. Association of HLA class I and class II alleles with myositis in Japanese patients. J Rheumatol 1998;25:1109-14.
7. Rider LG, Shamim E, Okada S et al. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: A tole of two loci. Arthritis Rheum 1999;42:1285-90.
8. Shamim EA, Rider LG, Pandey JP et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: Ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002;46:1885-93.
9. Chinoy H, Salway F, Fertig N et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006;8:R13.
10. O'Hanlon TP, Carrick DM, Arnett FC et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic; groups in caucasians. Medicine (Baltimore) 2005;84:338-49.
11. O'Hanton TP, Carrick DM, Targoff IN et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006;85:111-27.
12. Zeggini E, Thomson W, Kwiathowski D, Richardson A, Ollier W, Donn R. Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. Arthritis Rheum 2002;46:3304-11.
13. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 2004;5:315-29.
14. Pachman LM, Liotta-Davis MR, Hong DK et al. TNFalpha308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor alpha, disease duration and pathologic calcifications. Arthritis Rheum 2000;43:2368-77.
15. Werth VP, Callen JP, Ang G, Sullivan KE. Associations of Tumor Necrosis Factor Alpha and HLA Polymorphisms with Adult Dermatomyositis: Implications for a unique pathogenesis. J Invest Dermatol 2002;119:617-20.
16. Hassan AB, Nikitina-Zake L, Sanjeevi CB, Lundberg IE, Padyukov L. Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/ DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 2004;50:1013-5.
17. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
18. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990;87:1233-7.
19. Lio D, Candore G, Colombo A et al. A genetically determined high setting of TNF-[alpha] influences immunologic parameters of HLA-B8,DR3 positive subjects: Implications for autoimmunity. Human Immunology 2001;62:705-13.
20. Louis E, Franchimont P, Piron A et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood call culture in healthy humans. Clinical & Experimental Immunology 1998;113;401-6.
21. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
23. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
25. Preliminary criteria for the classification of systemic sclerosis (sclaroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;3:581-90.
26. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
27. Vitall C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
28. Alarcon-Segovia D. Mixed connective tissue disease and overlap syndromes. Clin Dermatol 1994;12:309-16.
29. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-49.
30. Riboli E. Nutrition and cancer background and rationale of the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Oncol 1992;3:783-91.
31. Symmons DP, Bankhead CR, Harrison BJ et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: Results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997;40:1955-61.
32. Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682-9.
33. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995;59(Pt 1)97-105.
34. Payami H, Joe S, Farid NR et al. Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. Am J Hum Genet 1989;45:541-6.
35. Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007, [Epub ahead of print March 28].
36. Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: Effect of multiple gene interactions. Autoimmunity Reviews 2002;1:29-35.
37. Hassan AB, Fathi M, Dastmalchi M, Lundberg IE, Padyukov L. Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun 2006;27:62-8.